Astra IDL takeover: Pricing logic - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Astra IDL takeover: Pricing logic

Dec 21, 2000

The takeover of a majority stake in Astra IDL by the foreign partner marks the end over the control over the company. The surprise, however is the price paid to the Hindujas. At Rs 670 per share it amounts to almost 25 times the per share earnings of the last year. Astra’s product portfolio is not too lucrative either. It has so far been focussed on anti–infectives and anti–malarials, which are the relatively slower growing segments of the pharmaceutical market. It’s major brand, the cough syrup Linctus Codeinae (a cough syrup) doesn’t enjoy the brand equity that its competitors Corex (Pfizer) or Phensedyl (Rhone Poulenc) enjoy. The Hindujas anyway did not have any core competence in pharmaceuticals. So the company was heavily dependent on Astra for new product introductions.

Then why were the Hindujas paid Rs 670 per share? One answer could be the fact that the real estate on which the company’s plant is located. This is an estate of 70 acre located near the new Bangalore airport and could be worth around Rs 3.5 bn (Rs 700 per share).

The other reason could be the fact that Astra Zeneca did not have a presence in the pharmaceutical segment in India, though it had two 100% subsidiaries in the agrochemical segment. With Zeneca being hived off internationally (to be merged with Novartis’ agrochemical arm), Astra needed a presence in India which could happen only if they bought out the Hindujas.

Meanwhile, the share price has jumped from a range of Rs 260 (on November 23, 2000) to over Rs 413, over the last month possibly in anticipation of the takeover.

Equitymaster requests your view! Post a comment on "Astra IDL takeover: Pricing logic". Click here!


More Views on News

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

Krsnaa Diagnostics IPO Opens Tomorrow: Key Points to Consider (Views On News)

Aug 3, 2021

Krsnaa Diagnostics grey market premium is at around Rs 440 from its issue price of Rs 933-954.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

5 Indian Companies Embracing Blockchain Technology (Views On News)

Nov 23, 2021

Blockchain adoption in India was slow in the past. Now, the technology is being well received.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Dec 6, 2021 09:11 AM